[Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
L M
LM
Dobordzhginidze
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004359:Drug Therapy, Combination; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005340:Fibrinogen / Q000032:analysis; D006710:Homocysteine / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D008055:Lipids; D010919:Placebos; D014280:Triglycerides; D006710:Homocysteine; D005340:Fibrinogen; D002784:Cholesterol; D011345:Fenofibrate